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1Background and Purpose—The relationship between type 2 diabetes mellitus (T2D) and cerebral small vessel disease 
(CSVD) is unclear. We aimed to examine the causal effect of T2D, fasting glucose levels, and higher insulin resistance on 
CSVD using Mendelian randomization.
Methods—Five CSVD phenotypes were studied; 2 were clinical outcomes associated with CSVD (lacunar stroke: 
n=2191/27 297 and intracerebral hemorrhage [ICH]: n=2254/8195 [deep and lobar ICH]), whereas 3 were radiological 
markers of CSVD (white matter hyperintensities: n=8429; fractional anisotropy [FA]: n=8357; and mean diffusivity: 
n=8357). We applied 2 complementary analyses to evaluate the association of T2D with CSVD. First, we used summarized 
data from genome-wide association study to calculate the effects of T2D-related variants on CSVD with inverse-variance 
weighted and weighted median approaches. Second, we performed a genetic risk score approach to test the effects of 
T2D-associated variants on white matter hyperintensities, FA, and mean diffusivity using individual-level data in UK 
Biobank.
Results—T2D was associated with higher risk of lacunar stroke (odds ratio [OR], 1.15; 95% confidence interval [CI], 
1.04–1.28; P=0.007) and lower mean FA (OR, 0.78; 95% CI, 0.66–0.92; P=0.004) but not white matter hyperintensities 
volume (OR, 1.01; 95% CI, 0.97–1.04; P=0.626), higher mean diffusivity (OR, 1.04; 95% CI, 0.89–1.23; P=0.612), 
ICH (OR, 1.07; 95% CI, 0.95–1.20; P=0.269), lobar ICH (OR, 1.07; 95% CI, 0.89–1.28; P=0.466), or deep ICH (OR, 
1.16; 95% CI, 0.99–1.36; P=0.074). Weighted median and penalized median weighted analysis showed similar effect 
estimates of T2D on lacunar stroke and FA, but with wider CIs, meaning they were not significant. The genetic score on 
individual-level data was significantly associated with FA (OR, 0.63; 95% CI, 0.45–0.89; P=0.008) after adjusting for 
potential confounders.
Conclusions—Our Mendelian randomization study provides evidence to suggest that T2D may be causally associated with 
CSVD, in particular with lacunar stroke and FA.   (Stroke. 2018;49:00-00. DOI: 10.1161/STROKEAHA.117.020536.)
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Cerebral small vessel disease (CSVD) is an age-related disease affecting the small blood vessels of the brain.1,2 It 
accounts for at least 25% of all strokes and is the most com-
mon cause of vascular dementia.1,2 Several neuroimaging fea-
tures are associated with CSVD, including lacunar infarcts, 
white matter hyperintensities (WMH), enlarged perivascular 
spaces, microbleeds, and brain atrophy. Intracerebral hemor-
rhages (ICH), particularly those arising from deep perforat-
ing small vessels, are also believed to be caused by CSVD.2 
In addition, diffusion tensor imaging measures, such as frac-
tional anisotropy (FA) and mean diffusivity (MD), are thought 
to capture microstructural changes of the white matter related 
to CSVD.3
However, the pathogenesis of CSVD is still uncertain,2 and 
consequently few effective and mechanism-based treatments 
for CSVD are available, aside from management of vascular 
risk factors of CSVD.2 Understanding which vascular risk 
factors are truly causal and improved understanding of how 
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these pathological processes relate to different neuroimaging 
features of CSVD has the potential to improve treatment and 
prevention of CSVD.
Type 2 diabetes mellitus (T2D) is an established risk factor 
for ischemic stroke and cognitive decline.4,5 Epidemiological 
studies have suggested that T2D is associated with lacunar 
stroke,6,7 but the relationships of T2D with WMH, ICH, and 
other radiological markers of CSVD have been inconsistent.4,6–9 
Such studies are also limited by the study design, which can 
be confounded. Therefore, a definitive causal association 
between T2D and CSVD is yet to be established. In addition, 
few studies have specifically studied the relationship between 
higher insulin resistance and fasting glucose levels and risk 
of CSVD,10–12 leaving a gap in knowledge regarding whether 
either is the driving force behind increased risk of CSVD.
Mendelian randomization (MR), using genetic variants 
as instrumental variables, is a method that enables stronger 
claims to be made about the causality of risk factors in disease 
pathogenesis.13 It is based on the theory that genetic variants 
are randomly allocated at meiosis, similar to a randomized 
controlled trial.14 Therefore, genetic variants are independent 
of many other factors that bias observational studies, such as 
confounding and reverse causation. In the absence of plei-
otropy, a significant association in an MR study between an 
exposure and outcome implies causality. In the present study, 
we aimed first to use MR to determine whether T2D is caus-
ally associated with clinical outcomes associated with CSVD; 
lacunar stroke and ICH; as well as intermediate radiological 
markers of CSVD; WMH, FA and MD. Second, we performed 
exploratory analyses investigating the relationship between 
higher insulin resistance and fasting glucose levels and risk 
of CSVD. All analyses are based on the aggregate effects of 
genetic variants rather than clinically diagnosed T2D.
Methods
The data that support the findings of this study are available from the 
corresponding author on reasonable request.
Study Design, Data Sources, and Ethical Approval
We performed a MR analysis, testing the causal relationship of T2D, 
fasting glucose, and fasting insulin with 5 manifestations of CSVD 
(magnetic resonance imaging–confirmed lacunar stroke, ICH [alone 
and stratified by the location of hemorrhage: deep ICH and lobar 
ICH], WMH, FA, and MD). Analyses of all CSVD phenotypes were 
based on subjects of European ancestry only.
For ICH, we used a data set composed of 2254 cases and 8195 
controls from 3 studies. One thousand five hundred forty-five 
cases and 1481 controls were from the Intracerebral Hemorrhage 
Genetics Collaboration and downloaded from the Cerebrovascular 
Disease Knowledge Portal (http://cerebrovascularportal.org).15 
Five hundred seventy-five cases and 5750 propensity score–
matched controls (matched on age, sex, and ancestry-informative 
principal components) were from UK Biobank, based on algo-
rithmically defined ICH in White British subjects.16 One hundred 
thirty four cases and 964 controls were from the Cambridge ICH 
Genetics Study. For full details, Methods section in the online-only 
Data Supplement.
The magnetic resonance imaging–confirmed lacunar stroke data 
were derived from 2191 lacunar stroke cases with magnetic reso-
nance imaging confirmation from the SIGN-NINDS,17 WTCCC2,18 
and DNA lacunar genome-wide association studies and 27 297 con-
trols.19 All cases were obtained based on hospital admissions.
Radiological markers of CSVD were derived from UK Biobank. 
Procedures for brain imaging acquisition and initial quality check 
have been described previously and are available on the UK Biobank 
website (Brain Imaging Documentation V1.3, http://www.ukbiobank.
ac.uk).20 For FA and MD, we analyzed the first principal component 
of mean FA or MD values across 48 standard space tracts in 8357 
individuals. WMH data were based on an analysis of 8429 subjects 
from UK Biobank. Additional details are provided in the Methods 
section in the online-only Data Supplement.
Study characteristics for each of the data sets are provided in 
Table 1.
An IRB or regional review board has approved the use of human 
subjects in each of the study populations. All patients gave informed 
consent. UK Biobank received ethical approval from the research eth-
ics committee (REC reference 11/NW/0382). The present analyses 
were conducted under UK Biobank application number 19463.
Single-Nucleotide Polymorphism Selection
We selected single-nucleotide polymorphisms (SNPs) associated 
with T2D, fasting insulin, and fasting glucose, which reached 
genome-wide significance in the largest genome-wide association 
meta-analyses to date.21–23 Eighty-four SNPs were included for 
T2D, 36 for fasting glucose, and 18 for fasting insulin (Table I in 
the online-only Data Supplement). In instances where SNPs were 
not available in a data set because of poor imputation quality, we 
replaced them with proxy SNPs if available (r2>0.7). We included 
only 1 SNP from any associated locus. We verified that SNPs were 
uncorrelated by performing LD clumping (r2>0.1, 100 kb) using 
PLINK.24
Statistical Analyses
We performed 2 complementary analyses to evaluate the impact 
of T2D-associated variants on CSVD phenotypes. For our primary 
analysis of the association of T2D with all CSVD phenotypes using 
2-sample MR on summary statistics, we used a significance threshold 
Table 1. Cohort Characteristics
CSVD Phenotypes N Age, Mean (SD) % Male
% Diabetes 
Mellitus % Hypertension
MRI-confirmed lacunar stroke 2191 cases, 27 297 controls 65 (14) 63 19 71
Intracerebral hemorrhage 2254 cases, 8195 controls ICH GWAS: 67 (10)
Cambridge ICH: 71 (13)
UK Biobank: 61 (7)
ICH GWAS: 55
Cambridge ICH: 55
UK Biobank: 57
N/A N/A
Deep intracerebral hemorrhage 957 cases, 2445 controls
Lobar intracerebral hemorrhage 722 cases, 2445 controls
White matter hyperintensity 8429 62 (7) 48 3 46
Fractional anisotropy 8357 62 (7) 48
Mean diffusivity 8357 62 (7) 48
CSVD indicates cerebral small vessel disease; and N/A, not available.
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of P<0.0071, equivalent to Bonferroni correction for 7 independent 
tests. For radiological markers of CSVD, we performed a confirma-
tory analysis using individual-level data in UK Biobank:
Two-Sample MR Using Summary Statistics
We assessed the impact of risk factor–associated SNPs on each 
CSVD phenotype using MR approaches. Our primary analysis 
used an inverse-variance weighted meta-analysis approach (con-
ventional MR). We then performed secondary analyses using 
weighted median and penalized weighted median approaches. We 
assessed the potential role of directional pleiotropy by testing if 
the intercept from MR-Egger regression was significantly differ-
ent from zero.
As sensitivity analysis, we performed a look-up of all the 
SNPs used in our study in Phenoscanner (http://www.phenoscan-
ner.medschl.cam.ac.uk/phenoscanner) to evaluate whether these 
SNPs were associated with other traits at genome-wide signifi-
cance level which may affect our results. We found 8 SNPs related 
to T2D (rs2925979, rs2943640, rs3794991, rs3923113, rs429358, 
rs459193, rs635634, and rs780094), which were also associated 
with lipids and kidney function, as well as 4 SNPs for fasting 
glucose (rs174550, rs17762454, rs780094, and rs983309) and 
9 SNPs for fasting insulin (rs10195252, rs1530559, rs2126259, 
rs2745353, rs2943645, rs3822072, rs459193, rs731839, and 
rs780094). We then reassessed the results after excluding these 
SNPs. Additionally, for significant findings, we assessed the 
potential that the association was mediated by body mass index 
(BMI) by performing a sensitivity analysis, removing 8 SNPs, 
which are also associated with BMI at genome-wide significance 
(rs2943640, rs11671664, rs12970134, rs8050136, rs10146997, 
rs5215, and rs7903146). All analyses were performed using the 
Mendelian Randomization and gtx libraries in R version 3.3.2 
(https://www.R-project.org/).
Two-Sample MR Using Genetic Risk 
Scores on Individual-Level Data
For each of the 84 SNPs associated with T2D, we constructed a 
genetic risk score for each individual in UK Biobank by multiply-
ing the log of the odds ratio (OR) for association with T2D by the 
number of risk alleles and summing this value for each individual. 
We then used a linear regression model to evaluate the effect of the 
genetic score on WMH, FA, and MD, with adjustment for genotyp-
ing batch, age, sex, BMI, blood pressure, and ancestry-informative 
principal components to control for these potential confounding 
factors.
We also assessed their associations by constructing quartiles of the 
genetic score and calculated the ORs and 95% confidence interval 
(CI) for the score quartiles using quantile 1 as a reference, thus quan-
tile 2 versus quantile 1, quantile 3 versus quantile 1, and quantile 4 
versus quantile 1.
Results
MR Results: Associations of T2D 
With CSVD Phenotypes
Conventional MR estimates for the effect of T2D on clini-
cal outcomes associated with CSVD (lacunar stroke, ICH, 
deep ICH, and lobar ICH) and radiological markers of CSVD 
(WMH, FA, and MD) are displayed in the Figure and Table 2.
T2D was associated with higher risk of lacunar stroke (OR, 
1.15; 95% CI, 1.04–1.28; P=0.007) and lower mean FA (OR, 
0.78; 95% CI, 0.66–0.92; P=0.004). Conversely, we did not 
find any significant associations of T2D with WMH volume 
(OR, 1.01; 95% CI, 0.97–1.04; P=0.626) and higher mean 
MD (OR, 1.04; 95% CI, 0.89–1.23; P=0.612). Regarding 
the effect of T2D on ICH, lobar ICH, and deep ICH, none 
were found to be significant (ICH risk: OR, 1.07; 95% CI, 
0.95–1.20; P=0.269; lobar ICH risk: OR, 1.07; 95% CI, 0.89–
1.28; P=0.466; deep ICH risk: OR, 1.16; 95% CI, 0.99–1.36; 
P=0.074). Although nonsignificant, the odds ratio for associa-
tion with deep ICH was near significant with an OR and direc-
tion of effect similar to that seen for lacunar stroke.
Weighted median and penalized median weighted analysis 
yielded similar effect estimates of T2D on lacunar stroke and 
FA, but the CIs were wide, so were not significant (Table 2). 
To assess the robustness and consistency of the results, we 
also conducted a sensitivity analysis by excluding the SNPs 
associated with lipids and kidney function at genome-wide 
significance level. In this sensitivity analysis, the associations 
of T2D with lacunar stroke and FA remained significant (Table 
III in the online-only Data Supplement). To assess whether the 
results were influence by BMI, we repeated the analyses for 
T2D and lacunar stroke as well as T2D and FA, both of which 
showed only minor differences after removing the SNPs 
(lacunar stroke: OR, 1.14; 95% CI, 1.01–1.29; P=0.028 and 
FA: OR, 0.78; 95% CI, 0.64–0.94; P=0.0095).
MR-Egger regression showed no evidence of directional 
pleiotropy for the effects of T2D on lacunar stroke (inter-
cept=0.008; P=0.515), ICH (intercept=0.009; P=0.528), deep 
ICH (intercept=0.022; P=0.218), lobar ICH (intercept=0.014; 
P=0.539), WMH (intercept=0.003; P=0.518), FA (inter-
cept=−0.003; P=0.901), and MD (intercept=0.004; P=0.869).
Figure. Mendelian randomization esti-
mates for the effect of type 2 diabetes 
mellitus (T2D) on cerebral small vessel 
disease (CSVD) phenotypes. Analyses 
were performed with conventional Men-
delian randomization analysis (inverse-
variance weighted method). CI indicates 
confidence interval; and OR, odds ratio.
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Genetic Risk Score Analyses: Effects 
of T2D on WMH, FA, and MD
Results of the T2D genetic risk score on WMH, FA, and MD 
are presented in Table 3. The genetic score including 84 T2D-
associated SNPs was significantly associated with FA (OR, 
0.63; 95% CI, 0.45–0.89; P=0.008) after adjustment for geno-
typing batch, age, sex, BMI, blood pressure, and ancestry-
informative principal components. We note that this result 
is significant when correcting for the 3 phenotypes studied 
in this secondary analysis but does not reach P<0.0071, the 
threshold used in our primary analysis. Conversely, the risk 
score was not significantly associated with WMH (OR, 1.01; 
95% CI, 0.94–1.09; P=0.727) or MD (OR, 1.09; 95% CI, 
0.78–1.52; P=0.613).
Stratifying by quartiles of the genetic score, we only found 
a nominally significant effect of quantile 4 compared with 
quantile 1 of the score on FA (OR, 0.73; 95% CI, 0.57–0.94; 
P=0.015).Odds ratios±SE for WMH, FA, and MD based 
on the quartiles of the genetic score were plotted (Figures I 
through III in the online-only Data Supplement).
Associations of Fasting Glucose and 
Insulin With CSVD Phenotypes
Fasting glucose and insulin were not associated with 
any CSVD phenotypes (lacunar stroke, ICH, deep ICH, 
lobar ICH, WMH, FA, and MD) in the present study using 
inverse-variance weighted, weighted median, or MR-Egger 
regression methods (Table II in the online-only Data 
Supplement).
Discussion
Prevention and management of CSVD is limited by our under-
standing of causal factors underlying the disease process. T2D 
is an established risk factor for CSVD, but a causal relationship 
is yet to be determined, and its impact on different CSVD phe-
notypes is not well understood. Using genetic data via an MR 
approach, we assessed the causal relationship between T2D 
and different CSVD phenotypes. Our primary analysis showed 
that a genetic predisposition to T2D was related to lacunar 
stroke and FA. We performed secondary analyses using an 
alternative weighted median method, which showed similar 
effects but wider CIs. Evidence indicating that the associations 
are robust is provided by the fact that (1) the results remained 
in sensitivity analyses removing pleiotropic SNPs and (2) asso-
ciations with FA were significant when performing an alterna-
tive analysis based on individual-level data in UK Biobank, in 
which we were able to adjust for potential confounding factors.
The results were consistent with previous observational 
studies showing a positive association of T2D with risk of 
lacunar stroke6,7 and an MR analysis using small artery occlu-
sion strokes based on the TOAST classification (Trial of ORG 
10172 in Acute Stroke Treatment).25 However, the OR values 
Table 2. Mendelian Randomization Estimates for the Effect of T2D on CSVD Phenotypes Using Inverse-Variance 
Weighted, Weighted Median, and Penalized Weighted Median Methods
CSVD Phenotypes
Inverse-Variance Weighted Weighted Median Penalized Weighted Median
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
MRI-confirmed lacunar stroke 1.15 (1.04–1.28) 0.007 1.19 (0.98–1.43) 0.075 1.19 (0.98–1.44) 0.076
Intracerebral hemorrhage 1.07 (0.95–1.20) 0.269 1.10 (0.89–1.35) 0.370 1.10 (0.89–1.35) 0.367
Deep intracerebral hemorrhage 1.16 (0.99–1.36) 0.074 1.06 (0.81–1.38) 0.697 1.05 (0.80–1.38) 0.743
Lobar intracerebral hemorrhage 1.07 (0.89–1.28) 0.466 1.15 (0.83–1.61) 0.399 1.16 (0.82–1.62) 0.401
White matter hyperintensity 1.01 (0.97–1.04) 0.626 0.98 (0.92–1.04) 0.528 0.98 (0.92–1.04) 0.534
Fractional anisotropy 0.78 (0.66–0.92) 0.004 0.74 (0.54–1.02) 0.068 0.74 (0.54–1.02) 0.064
Mean diffusivity 1.04 (0.89–1.23) 0.612 1.08 (0.81–1.45) 0.598 1.08 (0.81–1.45) 0.582
Significance threshold was set at P<0.0071. CI indicates confidence interval; CSVD, cerebral small vessel disease; OR, odds ratio; and T2D, 
type 2 diabetes mellitus.
Table 3. Association of the T2D-Related SNPs With WMH, FA, and MD in UK Biobank Using Linear Regression*
White Matter Hyperintensity Fractional Anisotropy Mean Diffusivity
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Multi-SNP score 1.01 (0.94–1.09) 0.727 0.63 (0.45–0.89) 0.008 1.09 (0.78–1.52) 0.613
Quantile 1 Ref Ref Ref Ref Ref Ref
Quantile 2† 0.98 (0.93–1.04) 0.521 0.82 (0.64–1.06) 0.126 0.96 (0.75–1.23) 0.745
Quantile 3† 0.99 (0.94–1.04) 0.604 0.84 (0.66–1.08) 0.173 0.89 (0.69–1.13) 0.337
Quantile 4† 1.01 (0.96–1.06) 0.661 0.73 (0.57–0.94) 0.015 1.03 (0.81–1.32) 0.788
CI indicates confidence interval; FA, fractional anisotropy; MD, mean diffusivity; OR, odds ratio; SNP, single-nucleotide polymorphism; 
T2D, type 2 diabetes mellitus; and WMH, white matter hyperintensity.
*Adjustment for genotyping batch, age, sex, body mass index, blood pressure, and ancestry-informative principal components.
†We constructed quartiles of the genetic score, and OR and 95% CI for the multi-SNP score quartiles were generated for quantile 2, 
quantile 3, and quantile 4 relative to quantile 1 (quantile 2 vs quantile 1, quantile 3 vs quantile 1, and quantile 4 vs quantile 1).
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of the relationship between T2D and lacunar stroke from a 
meta-analysis published in 20066 ranged from 1.3 to 2.2 in dif-
ferent cohorts, which were larger than our MR analyses (OR, 
1.15; 95% CI, 1.04–1.28). This may be explained by the fact 
that previous observational epidemiological associations may 
have been influenced by potentially important confounders 
such as sex, blood pressure, and dietary factors. It should also 
be noted that the OR in our study refers to the increased risk 
associated with genetic markers related to T2D. Therefore, as 
these do not capture the total variance associated with T2D, 
the estimate is likely to be smaller than those from epidemio-
logical studies.
Studies of the association between T2D and pathogenic sub-
types of ICH are limited, but a recent meta-analysis9 included 
19 case–control studies has reported that hemorrhagic stroke 
was 1.23-fold more prevalent in patients with diabetes melli-
tus, whereas the association was not observed in 3 population-
based cohort studies.26–28 Our study using an MR approach 
showed no significant associations of T2D on total ICH risk, 
and on different location of ICH risk (lobar and deep ICH29,30). 
Although not significant, the effect of T2D on deep ICH was 
similar to that seen in lacunar stroke, which is consistent with 
the idea that deep ICH is associated with CSVD. However, we 
had limited power because of the small sample size for ICH, 
and this needs to be studied in larger data sets.
To better assess the causality of the associations between 
T2D and cerebral white matter injury, we used macrostruc-
tural (WMH volume) and microstructural (FA and MD) 
brain magnetic resonance imaging measures for the total 
brain. First, both MR approach and genetic score analy-
ses did not show any significant associations between T2D 
and WMH volume, which was similar to the results from 2 
recent reviews6,7 showing uncertainty for the effect of T2D 
on WMH. In addition, data from a randomized controlled 
trial study31 found that intensive control of diabetes mellitus 
(hemoglobin A1c <6.0%) did not impede WMH progres-
sion and conversely caused more serious WMH for unclear 
reasons.
Second, FA and MD are 2 commonly used diffusion ten-
sor imaging indices, which are highly sensitive to subtle white 
matter changes.32 A few observational studies33–36 have shown 
a decreased FA and increased MD in T2D patients compared 
with controls, and the results were largely independent of 
WMH volume, which suggested that microstructural integrity 
damage likely precedes WMH, and diffusion tensor imaging 
indices maybe early markers for brain damage in patients with 
T2D. The results from the current study partly confirmed the 
findings from these aforementioned observational studies. We 
found the significant association between T2D and FA using 
MR methods, which also remained consistent in genetic score 
analyses. Surprisingly, T2D was not significantly associated 
with increased MD, and the reason for this discrepancy is 
unclear. It has been suggested that FA decrease maybe modu-
lated more directly by myelin alterations, whereas MD is more 
sensitive to cellularity, edema, and necrosis.37 Our results 
might, therefore, point to demyelination being an important 
factor in T2D patients.
Strengths of our MR analysis include the use of multiple 
T2D SNPs, which enable us to construct a polygenic score 
to increase the precision of the estimates. In combination, 
the SNPs explained between 5% and 10% of the variance of 
T2D. Ours is the first MR study to investigate the relationship 
between T2D and CSVD phenotypes, and the design of MR 
study can prevent reverse causation and potential confounding 
factors,13,14 such as lifestyle and dietary preference. However, 
there are some limitations in our MR study. First, in some 
of our MR analyses, the sample size was relatively small, 
which resulted in limited statistical power in the respective 
analyses, especially for the ICH analysis stratified by hemor-
rhage location. Second, effects of the genetic variants on T2D 
were obtained largely from European populations, and all the 
subjects included in our study were Europeans. Therefore, 
the results may not be generalizable to other populations. 
Additionally, we note that differences in baseline characteris-
tics between the T2D and CSVD populations might have sub-
tle influences on the effect estimates, meaning that OR values 
given here should be interpreted with this caveat. Limitations 
of MR include the potential for residual pleiotropy that could 
have influenced the results when T2D-associated SNPs also 
influence other traits. We note that this is often challenging 
to rule out with absolute certainty.38 One possible pleiotropic 
pathway in this analysis is through elevated BMI. From the 
results presented here, we cannot rule out partial mediation of 
the genetic effects through this pathway. Finally, our signifi-
cant association of T2D with lacunar stroke and FA was not 
confirmed after conducting weighted median and penalized 
weighted median methods. However, the weighted median 
approaches showed a similar effect size. MR studies with 
larger samples are, therefore, needed to confirm this result 
in the future.
Conclusions
Our MR study is consistent with a causal association between 
T2D and CSVD. In particular, we found evidence of asso-
ciations with lacunar stroke and FA. Further MR studies 
with larger sample sizes are required to determine this with 
more certainty and to rule out associations with other CSVD 
phenotypes.
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SUPPLEMENTAL MATERIAL
Table I. Single nucleotide polymorphism used as instrumental variables in the Mendelian
randomization analyses of type 2 diabetes, fasting glucose, and fasting insulin
SNP Closest gene Risk factor Effect allele Risk factor Beta
rs10146997 NRXN3/DIO2 T2D G 0.068
rs10193447 BCL11A T2D T 0.068
rs10238625 DGKB T2D A 0.068
rs10507349 RNF6 T2D A -0.056
rs1061810 HSD17B12 T2D A 0.077
rs10811661 CDKN2A/2B T2D C -0.156
rs10830963 MTNR1B T2D G 0.094
rs10842994 KLHDC5 T2D T -0.081
rs1111875 HHEX T2D T -0.107
rs11123406 BCL2L11 T2D C -0.049
rs111669836 MAP3K11 T2D A 0.068
rs11257655 CDC123 T2D T 0.077
rs11671664 GIPR T2D A 0.074
rs11708067 ADCY5 T2D G -0.104
rs11759026 CENPW T2D G 0.095
rs11787792 GPSM1 T2D A 0.130
rs1182436 MNX1 T2D C 0.077
rs12970134 MC4R T2D A 0.071
rs13266634 SLC30A8 T2D T -0.111
rs13292136 TLE4 T2D T -0.129
rs1359790 SPRY2 T2D A -0.077
rs1552224 ARAP1 T2D C -0.101
rs163184 KCNQ1 [1] T2D G 0.079
rs17106184 FAF1 T2D A -0.090
rs17168486 DGKB T2D T 0.093
rs1801282 PPARG T2D G -0.113
rs2023681 MTMR3/HORMAD2 T2D G 0.122
rs2050188 C6orf10 T2D T 0.051
rs2237897 KCNQ1 T2D C 0.223
rs2292626 PLEKHA1 T2D C 0.086
rs231360 KCNQ1 T2D T 0.077
rs2706785 TMEM155 T2D G 0.128
rs2796441 TLE1 T2D A -0.064
rs2925979 CMIP T2D T 0.077
rs2943640 IRS1 T2D C 0.082
rs329122 JADE2 T2D A 0.045
rs340874 PROX1 T2D C 0.060
rs35352848 UBE2E2 T2D T 0.086
rs3794991 GATAD2A|CILP2 T2D T 0.130
rs3821943 WFS1 T2D T 0.095
rs3923113 GRB14 T2D C -0.069
rs4238013 CCND2 T2D C 0.095
rs429358 APOE T2D T 0.122
rs4402960 IGF2BP2 T2D T 0.140
rs4457053 ZBED3 T2D A -0.080
rs459193 ANKRD55 T2D G 0.078
rs4774420 C2CD4A T2D C 0.077
rs4812829 HNF4A T2D A 0.053
rs516946 ANK1 T2D C 0.078
rs5215 KCNJ11 T2D T -0.075
rs576674 KL T2D A -0.073
rs60780116 ACSL1 T2D T 0.086
rs622217 SLC22A3 T2D C -0.053
rs635634 ABO T2D T 0.077
rs6813195 TMEM154 T2D T -0.064
rs6918311 SLC35D3 T2D A 0.068
rs702634 ARL15 T2D A 0.050
rs7041847 GLIS3 T2D G -0.042
rs7111341 MIR4686 T2D T 0.051
rs7224685 ZZEF1 T2D T 0.068
rs7428936 ADAMTS9 T2D T 0.068
rs7451008 CDKAL1 T2D C 0.174
rs756852 KCNQ1 T2D G 0.086
rs757209 HNF1B (TCF2) T2D G 0.086
rs7578597 THADA T2D C -0.138
rs7674212 SLC9B2 T2D T -0.063
rs780094 GCKR T2D C 0.055
rs78761021 GLP2R T2D G 0.068
rs7903146 TCF7L2 T2D T 0.329
rs79349575 GIP T2D A 0.068
rs7957197 HNF1A T2D A -0.077
rs7985179 MIR17HG T2D A -0.089
rs8042680 PRC1 T2D A 0.063
rs8050136 FTO T2D A 0.107
rs8056814 BCAR1 T2D G 0.148
rs810517 ZMIZ1 T2D C 0.086
rs864745 JAZF1 T2D C -0.085
rs9271774 HLA-DQA1 T2D C 0.095
rs944801 CDKN2B-AS1 T2D C 0.071
rs9505118 SSR1 T2D G -0.063
rs952471 HMG20A T2D G 0.077
rs9648716 BRAF T2D T 0.076
rs9687833 ANKRD55 T2D A 0.095
rs9940149 ITFG3|HCCA2 T2D A -0.062
rs10747083 P2RX2 Fasting glucose A 0.016
rs10811661 CDKN2B Fasting glucose T 0.027
rs10830963 MTNR1B Fasting glucose G 0.077
rs10885122 ADRA2A Fasting glucose G 0.022
rs11071657 VPS13C/C2CD4
A/B
Fasting glucose A 0.006
rs11558471 SLC30A8 Fasting glucose G 0.029
rs11603334 ARAP1 Fasting glucose G 0.019
rs11605924 CRY2 Fasting glucose A 0.019
rs11619319 PDX1 Fasting glucose G 0.021
rs11708067 ADCY5 Fasting glucose A 0.021
rs11715915 AMT Fasting glucose C 0.013
rs11920090 SLC2A2 Fasting glucose T 0.028
rs16913693 IKBKAP Fasting glucose T 0.047
rs174550 FADS1 Fasting glucose T 0.018
rs17762454 RREB1 Fasting glucose T 0.012
rs2191349 DGKB/TMEM19
5
Fasting glucose T 0.029
rs2302593 GIPR Fasting glucose C 0.014
rs2657879 GLS2 Fasting glucose G 0.011
rs340874 PROX1 Fasting glucose C 0.010
rs3783347 WARS Fasting glucose G 0.015
rs3829109 LOC728489 Fasting glucose G 0.018
rs4506565 TCF7L2 Fasting glucose T 0.019
rs4607517 GCK Fasting glucose A 0.055
rs4869272 PCSK1 Fasting glucose T 0.018
rs560887 G6PC2 Fasting glucose C 0.070
rs576674 KL Fasting glucose G 0.019
rs6072275 TOP1 Fasting glucose A 0.016
rs6113722 FOXA2 Fasting glucose G 0.038
rs6943153 GRB10 Fasting glucose T 0.016
rs7651090 IGF2BP2 Fasting glucose G 0.014
rs7708285 ZBED3 Fasting glucose G 0.009
rs780094 GCKR Fasting glucose C 0.028
rs7867224 GLIS3 Fasting glucose A 0.014
rs7944584 MADD Fasting glucose A 0.023
rs9368222 CDKAL1 Fasting glucose A 0.016
rs983309 PPP1R3B Fasting glucose T 0.025
rs10195252 GRB14 Fasting insulin T 0.018
rs1167800 HIP1 Fasting insulin A 0.015
rs1530559 YSK4 Fasting insulin A 0.013
rs17036328 PPARG Fasting insulin T 0.014
rs2126259 PPP1R3B Fasting insulin T 0.031
rs2745353 RSPO3 Fasting insulin T 0.015
rs2943645 IRS1 Fasting insulin T 0.016
rs3822072 FAM13A1 Fasting insulin A 0.010
rs459193 ANKRD55 Fasting insulin G 0.019
rs4846565 LYPLAL1 Fasting insulin G 0.015
rs4865796 ARL15 Fasting insulin A 0.016
rs6822892 PDGFC Fasting insulin A 0.010
rs6912327 C6orf107 Fasting insulin T 0.015
rs731839 PEPD Fasting insulin G 0.017
rs780094 GCKR Fasting insulin C 0.022
rs7903146 TCF7L2 Fasting insulin C 0.022
rs860598 IGF1 Fasting insulin A 0.012
rs974801 TET2 Fasting insulin G 0.016
Table II. Mendelian randomization estimates for the effect of Fasting glucose, and insulin on CSVD phenotypes using inverse-variance weighted,
weighted median and penalized weighted median methods
Lacunar stroke
OR(95%CI)       P
ICH
OR(95%CI)        P
Deep ICH
OR(95%CI)        P
Lobar ICH
OR(95%CI)        P
WMH
OR(95%CI)       P
FA
OR(95%CI)       P
MD
OR(95%CI)       P
Inverse-variance weighted
Fasting Glucose 1.10(0.63-1.90) 0.744 0.65(0.36-1.20) 0.167 0.75(0.32-1.74) 0.504 0.71(0.28-1.78) 0.464 1.16(0.97-1.40) 0.099 0.44(0.18-1.08) 0.073 1.85(0.76-4.52) 0.177
Fasting Insulin 1.52(0.45-5.08) 0.500 0.48(0.12-1.86) 0.288 0.18(0.03-1.05) 0.056 0.41(0.06-2.98) 0.378 1.04(0.69-1.54) 0.843 1.61(0.23-11.32) 0.635 0.67(0.09-4.74) 0.685
Weighted median
Fasting Glucose 1.14(0.53-2.44) 0.733 0.60(0.25-1.44) 0.249 0.47(0.14-1.54) 0.213 2.10(0.53-8.40) 0.294 1.01(0.78-1.32) 0.934 0.62(0.16-2.37) 0.484 1.99(0.49-8.18) 0.338
Fasting Insulin 2.11(0.39-11.39) 0.383 0.18(0.03-1.24) 0.081 0.19(0.02-2.28) 0.192 0.13(0.01-1.86) 0.133 1.10(0.64-1.91) 0.728 0.79(0.05-13.39) 0.868 0.48(0.03-8.17) 0.608
Penalized weighted
median
Fasting Glucose 1.16(0.54-2.48) 0.696 0.60(0.25-1.44) 0.249 0.47(0.14-1.54) 0.211 2.16(0.54-8.55) 0.275 1.01(0.78-1.31) 0.946 0.62(0.16-2.37) 0.484 2.01(0.46-8.77) 0.355
Fasting Insulin 2.38(0.44-12.89) 0.316 0.17(0.02-1.21) 0.077 0.17(0.01-2.04) 0.163 0.12(0.01-1.72) 0.119 1.10(0.64-1.91) 0.728 0.69(0.04-12.01) 0.802 0.38(0.02-6.46) 0.499
Abbreviations:CSVD=cerebral small vessel disease; CI = confidence interval; OR = odds ratio,ICH=Intracerebral haemorrhage, WMH=White matter hyperintensity, FA=Fractional anisotropy,
MD=Mean diffusivity.
*MR-Egger regression estimates could not be identified because the SNPs had similar magnitudes of association with fasting insulin.
Table III. Mendelian randomization estimates for the effect of each risk factor on CSVD phenotypes using inverse-variance weighted for sensitivity
analyses*
Lacunar stroke
OR(95%CI)       P
ICH
OR(95%CI)        P
Deep ICH
OR(95%CI)        P
Lobar ICH
OR(95%CI)        P
WMH
OR(95%CI)       P
FA
OR(95%CI)       P
MD
OR(95%CI)       P
Type 2 diabetes 1.17(1.05-1.31) 0.004 1.08(0.96-1.22) 0.193 1.16(0.98-1.38) 0.081 1.10(0.92-1.33) 0.300 1.02(0.98-1.06) 0.264 0.77(0.64-0.91) 0.002 1.08(0.91-1.27) 0.397
Fasting Glucose 1.03(0.58-1.84) 0.908 0.64(0.34-1.20) 0.166 0.87(0.36-2.08) 0.747 0.80(0.04-17.86) 0.889 1.17(0.97-1.41) 0.106 0.40(0.16-1.00) 0.051 1.75(0.69-4.42) 0.238
Fasting Insulin 5.68(0.86-37.46) 0.071 0.86(0.11-6.82) 0.889 0.92(0.05-15.41) 0.953 0.81(0.04-17.87) 0.889 1.23(0.66-2.28) 0.509 2.62(0.13-54.20) 0.534 1.54(0.07-32.28) 0.780
Abbreviations:CSVD=cerebral small vessel disease; CI = confidence interval; OR = odds ratio, ICH=Intracerebral haemorrhage, WMH=White matter hyperintensity, FA=Fractional anisotropy,
MD=Mean diffusivity.
*Excluded the SNPs associated with lipids and kidney function.
Table IV Studies included in the MRI-confirmed lacunar stroke collaboration
Cohorts Cases Controls
DNA LACUNAR 917
GENESIS (SR/ADDS) 299
PRESERVE 46
UK-WTCCC2 250
GERMANY-WTCCC2 37
MILANO 9
ASGC 23
SIGN:BRAINS 5
SIGN:GEOS 4
SIGN:GCNKSS 27
SIGN:MIAMISR 13
SIGN:GASROS 27
SIGN:ISGS 28
SIGN:KRAKOW 7
SIGN:LEUVEN 45
SIGN:BASICMAR 36
SIGN:SAHLSIS 31
SIGN:SPS3_EUR 345
SIGN:GRAZ 42
1958 BIRTH COHORT, NATIONAL BLOOD SERVICE 5175
DNA LACUNAR 968
KORA 797
SIGN:HRS 9286
SIGN:GRAZ 816
SIGN:LEUVEN 453
SIGN:KRAKOW 716
SIGN:ADHD 411
SIGN:MALMO 1362
SIGN:OAI 3201
SIGN:GEOS 519
SIGN:ASGS 1200
SIGN:HABC 1586
SIGN:INMA 807
TOTAL EUROPEAN 2191 27297
Standard thorough quality control was performed on each dataset separately. The data were then
aligned to the forward strand and imputed to the HRC reference panel. SNPs with MAF<0.01 or
INFO<0.5 were then removed and association analysis was carried out using RVTESTS including age,
sex, study group, and the first 10 principal components. The inflation of test statistics (λ) was equal
to the inflation expected for the sample size.
Figure I.  Odds ratios ± standard error for WMH (logWMH volume) based on multi-SNP score
(Quantile2 vs Quantile 1, Quantile 3 vs Quantile 1 and Quantile 4 vs Quantile 1)
Figure II.Odds ratios ± standard error for FA based on multi-SNP score(Quantile2 vs Quantile 1,
Quantile 3 vs Quantile 1 and Quantile 4 vs Quantile 1)
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Figure III. Odds ratios ± standard error for MD based on multi-SNP score (Quantile2 vs Quantile 1,
Quantile 3 vs Quantile 1 and Quantile 4 vs Quantile 1)
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Supplementary methods
UK Biobank genome-wide association study of FA, MD, and WMH
Study population and ethical approval
UK Biobank is a prospective study that recruited 500,000 community-dwelling participants from
across the UK between 2006 and 2010, aged 40–69 years (http://www.ukbiobank.ac.uk). The study
collects extensive data from questionnaires, interviews, health records, physical measures, biological
samples and imaging.
A subset of the participants also underwent brain MRI. In the present study we used the second
release of MRI data, which included 9,045 subjects who underwent brain MRI, on average 6.6 years
(SD 1.0 years) after initial recruitment at mean age 55.5 years (SD 7.4 years) and had usable T2 FLAIR
or DTI images. Patients with a baseline diagnosis of stroke (ICD-9/-10 or self-report or health-record
linkage), multiple sclerosis, Parkinson’s disease, dementia, any other neurodegenerative problem or
no genetic data were excluded. A further three participants with consistently extreme outlying tract-
averaged water diffusion biomarker values were removed following visual inspection of the data by
the authors, leaving 8,568 individuals for the current analysis.
UK Biobank received ethical approval from the research ethics committee (REC reference
11/NW/0382). All participants provided informed consent to participate. The present analyses were
conducted under UK Biobank application number 19463.
MRI
Procedures for brain imaging acquisition and initial quality check have been described previously and
are available on the UK Biobank website (Brain Imaging Documentation V1.3,
http://www.ukbiobank.ac.uk).1
In brief, all brain MRI data were acquired on a single standard Siemens Skyra 3T scanner (Siemens
Medical Solutions, Germany) using the standard Siemens 32-channel RF receiver head coil. Sagittal
T1-weighted scans were acquired using a 3D magnetization-prepared rapid acquisition gradient-echo
(MPRAGE) sequence (resolution 1 x 1 x 1 mm, field of view 208 x 256 x 256, TI/TR=880/2000 ms).
Sagittal T2-weighted fluid attenuated inversion recovery (FLAIR) scans were obtained using a 3D
SPACE sequence (resolution 1.05 x 1.0 x 1.0 mm, field of view 192 x 256 x 256, TI/TR=1800/5000 ms).
DTI scans were acquired with a spin-echo echo-planar imaging sequence and multi-shell acquisition
(b0 = 0 s/mm-2, b = 1,000 s/mm-2,  b = 2,000 s/mm-2, 100 distinct diffusion-encoding directions, 2 mm
isotropic voxels, field of view 104 x 104 x 72).
White matter hyperintensities
White matter hyperintensities (WMH) were automatically segmented using the combined T1 and T2-
FLAIR data as input in the BIANCA tool (Brain Intensity AbNormality Classification
Algorithm).2BIANCA is a fully-automated supervised method for WMH detection, based on the k-
nearest neighbour algorithm, which gives the probability per voxel of being WMH. The total WMH
volume was calculated from the voxels exceeding a probability of 0.9 of being WMH and located
within a white matter mask. Obtained values were adjusted for the total intracranial volume and log
transformed because of their skewed distribution.
Fractional anisotropy and mean diffusivity
Following gradient distortion correction and further correction for head movement and eddy
currents, diffusion tensors and scalar diffusion parameters (ie, FA and MD) were calculated by
feeding the b=1000 shell (50 directions) into DTIFIT within the FSL software.3 The FA maps were fed
into tract-based spatial statistics (TBSS) which aligns the FA map onto a standard-space white matter
skeleton. The resulting standard-space warp is applied to all other DTI outputs. MD images were
projected onto the skeleton, using the FA derived projection parameters. Subsequently the
skeletonised images were averaged across a set of 48 standard-space tract masks, similar to the
processing applied in the ENIGMA project (http://enigma.ini.usc.edu/protocols/dti-protocols).4,5
Principal component analysis (PCA) was applied on the 48 tracts to extract a latent measure. The
first principal component of FA (FA.PC1) and MD (MD.PC1) was used in subsequent analyses as
dependent variable.
Genetic data
We used the June 2017 release of the imputed genetic data from UK Biobank (downloaded on June 3,
2017). Details of the design of the arrays, sample processing and stringent quality control have been
described elsewhere.6In brief, two closely related arrays from Affymetrix, the UK BiLEVE Axiom array
(9.9% of individuals) and the UK Biobank Axiom array, were used to genotype approximately
805,426 markers with good genome-wide coverage. Phasing was performed using SHAPEIT3 and
imputation to a merged HRC reference panel (39,131,578 autosomal SNPs) and UK10K & 1000
Genomes Phase 3 panel was carried out using the IMPUTE4 package.6–8 Imputed genotypes were
available for 487,442 individuals in this study. From the resulting dataset, we excluded (1) individuals
that did not segregate with European samples based on PCA analysis, (2) individuals with high levels
heterozygosity and missingness (>5%), (3) individuals whose reported sex was inconsistent with sex
inferred from the genetic data. In addition, only SNPs imputed from the HRC panel were included in
this analysis.
Statistical analysis
In this analysis, we first subset the genetic data on the individuals that also had MRI imaging data.
We performed a genome-wide association study of FA, MD and log(WMH), using SNPTEST v2.5.4-
beta3 including age at MRI, sex, body mass index (BMI), genotyping batch, and the first 10 ancestry
informative principal components as covariates.
Intracerebral Haemorrhage Meta-analysis
Contributing Studies
1. Cambridge ICH Genetics Study.
Intracerebral Haemorrhage cases were recruited based on hospital admissions at St. George’s
Hospital, London and Addenbrooke’s Hospital, Cambridge as part of the St. George’s Stroke Register
and GENESIS studiesbetween 2002-2012. All cases were confirmed radiologically.
Unrelated Caucasian controls, free of clinical cerebrovascular disease, were obtained by random
sampling, stratified for age and sex, from general practice lists from the same geographical location
as the patients. All patients and controls underwent a standardized clinical assessment and
completed a standardized study questionnaire.
The genetic dataset, which included other individuals not eligible for this analysis, was genotyped on
the Illumina HumanCoreExome array. SNPs were excluded with MAF<0.01, genotype
missingness>3%, HWE p<1e-6 in controls, strand ambiguity (A/T or C/G) or evidence of differential
missingness by case-control status (p<0.05). Individuals were excluded if they had missingness>3%,
excess or reduced heterozygosity, showed evidence of relatedness with another individual (pi-
hat>0.1875), or failed a “sex-check” in PLINK. EIGENSTRAT was used to remove non-caucasian
individuals, and was then repeated to calculate ancestry-informative principal components. The
remaining 269,691 autosomal SNPs and 2,603 individuals were then imputed to the haplotype
reference consortium build 2016.1 using the Michigan Imputation Server.7Post-imputation, SNPs
were removed with poor imputation quality (INFO<0.5) or low minor allele frequency (MAF<.005).
Analysis of the relationship between genomewide SNP dosages and ICH was performed using
rvtests9,adjusting for age, sex and ancestry informative-principal components.
2. Intracerebral Haemorrhage Genetics Collaboration
The intracerebral Haemorrhage Genetics Collaboration is composed of 1,545 cases and 1481
controls from studies from the United States and Europe. Full details of the population, genotyping
and imputation are available elsewhere.10
3. UK Biobank ICH GWAS
We used the June 2017 release of the imputed genetic data from UK Biobank (downloaded on June 3,
2017). Details of the design of the arrays, sample processing and stringent quality control have been
described elsewhere.6In brief, two closely related arrays from Affymetrix, the UK BiLEVE Axiom array
(9.9% of individuals) and the UK Biobank Axiom array, were used to genotype approximately
805,426 markers with good genome-wide coverage. Phasing was performed using SHAPEIT3 and
imputation to a merged HRC reference panel (39,131,578 autosomal SNPs) and UK10K & 1000
Genomes Phase 3 panel was carried out using the IMPUTE4 package.6–8 Imputed genotypes were
available for 487,442 individuals in this study.
From the resulting dataset, we excluded (1) individuals not designated as ‘White British’ based on
central PCA analysis, (2) individuals with high levels heterozygosity and missingness (>5%), (3)
individuals whose reported sex was inconsistent with sex inferred from the genetic data. In addition,
only SNPs imputed from the HRC panel were included in this analysis.Post-imputation, SNPs were
removed with poor imputation quality (INFO<0.5) or low minor allele frequency (MAF<.005).
We used algorithmically defined intracerebral haemorrhage as our outcome. We derived a set of
controls at a 10:1 ratio based on propensity score matching on age, sex and ancestry-informative
principal components.
Analysis of the association between genome-wide genotype dosages and the resulting 575 cases and
5750 controls was performing using rvtests9adjusting for age, sex, and ancestry-informative principal
components.
We note that haemorrhage location information was not available in UK Biobank, meaning subgroup
(deep or lobar) analyses could therefore not be performed.
Meta-analysis Methods
The contributing datasets were analysed using a fixed-effects inverse variance weighted method
using METAL.11 Genomic Control was used to control for any residual inflation. Only SNPs present in
all 3 contributing datasets were considered in this analysis.
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